IL-12Rβ2fl/fl mice were generated at the Brown Transgenic Facility, as previously described (21 (link)). B6.129P2(SJL)-MyD88tm1Defr/J (MyD88fl/fl, Cat #: 008888), B6.129X1-Gt(ROSA)26Sortm1(EYFP)Cos/J (eYFP, Cat #: 006148), IL-18−/− (Cat #: 004130), and C57BL/6 (B6, Cat #: 000664) mice were purchased from Jackson Laboratory. B6.Cg-Tg(CD4-cre)1Cwi N9 (CD4cre, Cat #: 4196), Balb/c (Cat #: BALB-F), and B6.SJL (Cat #: 002014) mice were purchased from Taconic. IL-12Rβ2fl/fl CD4cre+/− and MyD88fl/fl eYFP+/− CD4cre+/− mice were generated and maintained in-house, along with littermate controls (IL-12Rβ2fl/+ CD4cre+/− and MyD88fl/+ eYFP+/− CD4cre+/−, respectively). Both age- and sex-matched female and male mice (6–26 weeks) were used for these studies; littermates were used as controls for MyD88 cKO and IL-12βR2 cKO mice. All experiments were performed in accordance to the Guide for the Care of Use of Laboratory Animals, as defined by the NIH (PHS Assurance #A3284–01). The Institutional Animal Care and Use Committee (IACUC) of Brown University reviewed, and approved, the animal protocols performed in this study. Animals were housed in an AAALAC-accredited and centralized research facility.